on Quantum Biopharma Ltd.
Quantum Biopharma Initiates Sentinel Dosing for Lucid-21-302 Trial in Australia
Quantum Biopharma Ltd., a biopharmaceutical company, announced the commencement of sentinel dosing in Australia for its Phase-1 multiple ascending dose clinical trial. This study evaluates the safety and pharmacokinetics of Lucid-21-302 in healthy adults. Lucid-21-302 is being developed for treating multiple sclerosis, as stated by Dr. Andrzej Chruscinski, the company's Vice-President of Scientific and Clinical Affairs.
Prof. Lakshmi Kotra highlighted that this trial phase is crucial for advancing towards human phase-2 efficacy trials. Concurrently, Quantum Biopharma has engaged multiple firms, including Agoracom and ITG, to bolster market awareness and share liquidity. These efforts align with Quantum's strategies to accelerate its clinical programs and strengthen its investment portfolio.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Quantum Biopharma Ltd. news